VIM and myeloid sarcoma: Since the CD8+ T cell response was directed to HLA-A*0201-binding peptides derived from the human proteins MYH9 and VIM in MS patients [21], we focused on their murine orthologues and synthetized 70 peptides from their sequences, predicted to bind the C57BL/6 MHC-I alleles H2-Kb or H2-Db.